The stock of Akero Therapeutics Inc (NASDAQ: AKRO) has increased by 3.48 when compared to last closing price of 39.61. Despite this, the company has experienced a 9.48% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-04-24 that NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. (“Akero” or “the Company”) (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/AKRO.
Is It Worth Investing in Akero Therapeutics Inc (NASDAQ: AKRO) Right Now?
The 36-month beta value for AKRO is also noteworthy at -0.08. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AKRO is 70.71M, and at present, short sellers hold a 7.76% of that float. The average trading volume of AKRO on April 25, 2025 was 1.43M shares.
AKRO’s Market Performance
AKRO stock saw a decrease of 9.48% in the past week, with a monthly decline of -9.39% and a quarterly a decrease of 56.69%. The volatility ratio for the week is 4.67%, and the volatility levels for the last 30 days are 7.62% for Akero Therapeutics Inc (AKRO). The simple moving average for the past 20 days is 6.54% for AKRO’s stock, with a 22.70% simple moving average for the past 200 days.
Analysts’ Opinion of AKRO
Many brokerage firms have already submitted their reports for AKRO stocks, with BofA Securities repeating the rating for AKRO by listing it as a “Buy.” The predicted price for AKRO in the upcoming period, according to BofA Securities is $63 based on the research report published on January 30, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AKRO reach a price target of $72, previously predicting the price at $50. The rating they have provided for AKRO stocks is “Buy” according to the report published on January 27th, 2025.
Citigroup gave a rating of “Buy” to AKRO, setting the target price at $65 in the report published on November 18th of the previous year.
AKRO Trading at -5.15% from the 50-Day Moving Average
After a stumble in the market that brought AKRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.81% of loss for the given period.
Volatility was left at 7.62%, however, over the last 30 days, the volatility rate increased by 4.67%, as shares sank -5.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.94% lower at present.
During the last 5 trading sessions, AKRO rose by +9.48%, which changed the moving average for the period of 200-days by +84.72% in comparison to the 20-day moving average, which settled at $38.47. In addition, Akero Therapeutics Inc saw 47.34% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKRO starting from Yale Catriona, who sale 9,073 shares at the price of $37.91 back on Apr 15 ’25. After this action, Yale Catriona now owns 95,034 shares of Akero Therapeutics Inc, valued at $343,962 using the latest closing price.
Cheng Andrew, the President and CEO of Akero Therapeutics Inc, sale 30,000 shares at $35.23 during a trade that took place back on Apr 10 ’25, which means that Cheng Andrew is holding 624,324 shares at $1,056,780 based on the most recent closing price.
Stock Fundamentals for AKRO
The total capital return value is set at -0.36. Equity return is now at value -39.22, with -35.85 for asset returns.
Based on Akero Therapeutics Inc (AKRO), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -6.31. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -61.14.
Currently, EBITDA for the company is -285.42 million with net debt to EBITDA at 1.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.38.
Conclusion
In summary, Akero Therapeutics Inc (AKRO) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
